Glenmark Pharma net profit falls 18 percent to Rs 173.13 crore in Q1
Total expenses were higher at Rs 3,037.05 crore as compared to Rs 2,552.43 crore in the same quarter a year ago, the company said.
New Delhi: Glenmark Pharmaceuticals Ltd on Friday reported an 18 per cent decline in consolidated net profit at Rs 173.13 crore in the first quarter ended June 30, 2023, impacted by higher expenses.
The company had posted a consolidated net profit of Rs 211.1 crore in the same quarter last fiscal, Glenmark Pharmaceuticals said in a regulatory filing
Consolidated total revenue from operations during the quarter under review stood at Rs 3,401.6 crore as against Rs 2,777.29 crore in the year-ago period.
Total expenses were higher at Rs 3,037.05 crore as compared to Rs 2,552.43 crore in the same quarter a year ago, the company said.
"The robust growth in sales was led by our branded markets in the RoW (rest of the world) region. Our Europe business performed significantly well on the back of a strong generics portfolio and continued gains in market share, in our leading respiratory brands," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.
The company's North America business remained stable, and India business continued to significantly outperform industry growth rates, he added.
Read also: Glenmark Gets CDSCO Panel Nod to study Indacaterol, Glycopyrrolate,Mometasone Furoate FDC drug
Sales from the formulation business in India in Q1 was at Rs 1,064.3 crore over Rs 1,035.2 crore in the previous corresponding quarter, a growth of 2.8 per cent, the company said, adding, in North America, sale of finished dosage formulations clocked Rs 808.5 crore as against Rs 662.8 crore in the same period a year ago.
RoW registered a revenue of Rs 551.2 crore as compared to Rs 422.6 crore in the same quarter last fiscal, Glenmark said, adding that its European operations revenue was at Rs 573.2 crore from Rs 330 crore in the year-ago quarter.
Read also: Bid to buy Glenmark Life for Rs 7000 crore: Nirma leads acquisition race with ChrysCap, Sekhmet
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.